Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

Part of paid clinical trials in New York, New York.

Sponsor
Pfizer
Study ID
NCT06462014
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix

Key Dates

Start date
Jun 19, 2024
Status verified
Nov 2025
Primary completion
Dec 13, 2024
Completion
Dec 13, 2024

Study Design

Enrollment
507 participants (actual)

Arms

  • Arm: Relugolix patients
    Patients who have initiated relugolix

Primary Outcome Measure

Number of Participants According to Geographic Region [ Time Frame: Baseline period = Up to 1 year prior to index date; available data observed retrospectively over 178 days in this study ]

Locations (1)

FacilityCityStateZIPSite coordinators
PfizerNew YorkNew York10001-

Related coverage on Hipa.ai

Find similar trials in New York, NY

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Pfizer· New York, NY

Related Studies